Flag of the European Union EU Clinical Trials Register Help

Clinical trials for No Smoking Day

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    553 result(s) found for: No Smoking Day. Displaying page 7 of 28.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2007-007275-16 Sponsor Protocol Number: InfQ-001 Start Date*: 2008-12-18
    Sponsor Name:Department of Infetious Diseases, Odense University Hospital
    Full Title: Antibiotic treatment in patients hospitalized with an acute exacerbation in chronic obstructive pulmonary disease. Effect of one day of antibiotic treatment compared t0 6 days of antibiotic treatme...
    Medical condition: Acute exacerbation of chronic ostructive pulmonary disease in hospitalized patients. All patients receive "standard of care", and 1 day of intravenous antibiotics. In addition patients are randomiz...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056971 Infective exacerbation of chronic obstructive airways disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005914-12 Sponsor Protocol Number: DB2116133 Start Date*: 2012-08-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005339-83 Sponsor Protocol Number: IPA101985 Start Date*: 2006-05-19
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A two-centre, randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with repeat doses of inhaled GSK256066 on the allergen-induced late asthmat...
    Medical condition: Allergen-induced late asthmatic response
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003567 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003323-11 Sponsor Protocol Number: ITIBU001 Start Date*: 2014-10-01
    Sponsor Name:"Sapienza" University of Rome
    Full Title: RANDOMIZED CLINICAL TRIAL, PLACEBO-CONTROLLED, SPLIT-MOUTH, A DOUBLE-BLIND, FOR THE EVALUATION OF THE EFFECTIVENESS OF PREemptive ANALGESIA BY ADMINISTRATION OF IBUPROFEN 400MG, FOR THE CONTROL ...
    Medical condition: POST-OPERATIVE ACUTE PAIN (DAPO)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10031009 Oral pain PT
    17.1 10017947 - Gastrointestinal disorders 10030973 Oral discomfort PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023311-34 Sponsor Protocol Number: CPA 368-10 Start Date*: 2011-02-04
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A prospective, randomized, double blinded, crossover, two-treatment, two-sequence, short term pharmacokinetic, pharmacodynamic and tolerability, single centre study to compare AOP200704 vs. Esmolol...
    Medical condition: healthy male and female volunteers, intended for the treatment of dobutamine-induced tachycardia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040752 Sinus tachycardia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-001391-37 Sponsor Protocol Number: B2C110165 Start Date*: 2007-08-14
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic...
    Medical condition: COPD patients (moderate)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007315-93 Sponsor Protocol Number: V00071 GM 101 1A Start Date*: 2008-03-25
    Sponsor Name:Pierre Fabre dermatologie
    Full Title: Human skin blanching essay comparing a new shampoo containing betamethasone dipropionate at 0.025% and 0.050% to three reference marketed formulations in healthy subjects
    Medical condition: As it's a Mc Kensie and Stoughton test, there is no medical condition to be investigated in this trial. The intended indication for the betamethasone dipropionate shampoo is seborrhoeic dermatitis ...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007173-20 Sponsor Protocol Number: V00071CR202 Start Date*: 2009-02-19
    Sponsor Name:Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre
    Full Title: Assessment of the activity of a new cream containing betamethasone dipropionate at 0.010%, 0.025% and 0.050% versus reference products using a vasoconstriction assay in healthy subjects.
    Medical condition: Topical treatment of inflammatory dermatosis linked to cutaneous dryness
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019381-90 Sponsor Protocol Number: p57 Start Date*: 2010-07-05
    Sponsor Name:universiteit Maastricht
    Full Title: an fMRI study on the effects of NicVAX and placebo on Central Nervous System activation and behaviour following a nicotine challenge
    Medical condition: Nicotine addiction/smoking
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056478 Nicotine addiction LLT
    12.1 10056484 Nicotine craving LLT
    12.1 10057852 Nicotine dependence LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000611-14 Sponsor Protocol Number: 201314 Start Date*: 2014-06-27
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive P...
    Medical condition: in subjects with Chronic Obstructive Pulmonary Disease COPD
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-005913-35 Sponsor Protocol Number: DB2116132 Start Date*: 2012-06-27
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-005087-10 Sponsor Protocol Number: CQVA149A2327 Start Date*: 2013-04-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD ...
    Medical condition: Patients with COPD, with moderate to severe airflow limitation and a smoking history of at least 10 pack years.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005615-92 Sponsor Protocol Number: CQBM076X2203 Start Date*: 2013-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A two part, double blind, placebo controlled, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple doses of QBM076 in patients with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) NL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001409-15 Sponsor Protocol Number: 201012 Start Date*: 2016-01-07
    Sponsor Name:GlaxoSmithKlineResearch & Developemnt Ltd
    Full Title: Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD.
    Medical condition: Subjects with COPD.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001827-38 Sponsor Protocol Number: DB2116961 Start Date*: 2014-08-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC/VI (Umeclidinium/Vilanterol) in a fixed dose combination with Indacaterol plus Tiotropium in symptomatic...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) RO (Completed) HU (Completed) SK (Completed) PL (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005864-11 Sponsor Protocol Number: A6631033 Start Date*: 2014-06-11
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS W...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SE (Completed) PL (Completed) SK (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002578-23 Sponsor Protocol Number: A3971013 Start Date*: 2007-01-11
    Sponsor Name:Pfizer Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UK- 432,097 DRY POWDER FOR INHALATION IN ADULTS WITH MODERATE TO SEVERE CHRONIC...
    Medical condition: Chronic obstructive pulmonary disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002069-32 Sponsor Protocol Number: RPL554-CO-302 Start Date*: 2020-11-25
    Sponsor Name:Verona Pharma PLC
    Full Title: A Phase III Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks in Patients with Moderate to Severe Chronic Obstructive Pulmonary D...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DK (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-004614-16 Sponsor Protocol Number: DIA-ALE-2004-01 Start Date*: 2005-09-29
    Sponsor Name:DIATER LABORATORIES S.A.
    Full Title: Alternaria alternata inmunotherapy effects on AMP and methacholine bronchial answer and on inflammation markers in exhaled air (nitric oxide) and in condensated air (pH and hydrogen peroxide) in a...
    Medical condition: Asthma and allergic rhinitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016732-12 Sponsor Protocol Number: MAP0004-CL-P203 Start Date*: 2010-01-21
    Sponsor Name:MAP Pharmaceuticals, Inc.
    Full Title: An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004...
    Medical condition: migraine
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 23:01:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA